235 related articles for article (PubMed ID: 22052826)
1. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Khuri FR
Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB
Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
de Mello RA; Gerós S; Alves MP; Moreira F; Avezedo I; Dinis J
PLoS One; 2014; 9(2):e86697. PubMed ID: 24516537
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
Frampton JE
Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L
Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117
[TBL] [Abstract][Full Text] [Related]
8. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
9. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Raucourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB
Ann Oncol; 2010 Oct; 21(10):1967-1973. PubMed ID: 20335368
[TBL] [Abstract][Full Text] [Related]
10. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
11. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
12. An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Péron J; Polivka V; Chabaud S; Poupart M; Ceruse P; Ramade A; Girodet D; Zrounba P; Fayette J
BMC Cancer; 2014 Jul; 14():504. PubMed ID: 25011678
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.
Argiris A; Kotsakis AP; Hoang T; Worden FP; Savvides P; Gibson MK; Gyanchandani R; Blumenschein GR; Chen HX; Grandis JR; Harari PM; Kies MS; Kim S
Ann Oncol; 2013 Jan; 24(1):220-5. PubMed ID: 22898037
[TBL] [Abstract][Full Text] [Related]
14. New approaches to enhance chemotherapy in SCCHN.
Bourhis J
Ann Oncol; 2005; 16 Suppl 6():vi20-vi24. PubMed ID: 15987992
[TBL] [Abstract][Full Text] [Related]
15. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Agulnik M
Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
[TBL] [Abstract][Full Text] [Related]
16. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.
Blick SK; Scott LJ
Drugs; 2007; 67(17):2585-607. PubMed ID: 18034592
[TBL] [Abstract][Full Text] [Related]
19. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma.
Surmeli ZG; Ozveren A; Arslan C; Degirmenci M; Karaca B; Uslu R
Indian J Cancer; 2019; 56(1):4-8. PubMed ID: 30950435
[TBL] [Abstract][Full Text] [Related]
20. Current treatment options for metastatic head and neck cancer.
Price KA; Cohen EE
Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]